A 45-year-old woman presents with a 12-month history of irregular menstrual cycles, hot flushes, and mood changes. She requests contraception as she remains sexually active. Her last menstrual period was 8 weeks ago. She has a BMI of 28 kg/m², blood pressure 135/85 mmHg, and no significant medical history. She smokes 5 cigarettes per day. What is the most appropriate management approach?
Q92
A 34-year-old woman with well-controlled rheumatoid arthritis on methotrexate 15 mg weekly requests contraception. She is in a new relationship and wishes to avoid pregnancy while continuing her current treatment. She has no other medical conditions, does not smoke, and has a BMI of 23 kg/m². What is the most important counselling point regarding contraception for this patient?
Q93
A 52-year-old woman with a history of endometriosis presents with menopausal symptoms including severe hot flushes and night sweats for 6 months. She had a total hysterectomy without oophorectomy 8 years ago. Her FSH level is 67 IU/L. She is keen to start HRT but is concerned about symptom recurrence. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate initial HRT regimen?
Q94
A 27-year-old woman presents requesting contraception. She has a history of multiple sclerosis diagnosed 3 years ago with limited mobility. She is currently wheelchair-bound and experiences frequent urinary tract infections. Her BMI is 24 kg/m². She does not smoke and has no other significant medical history. She is in a stable relationship and has completed her family. What is the most appropriate contraceptive method for this patient?
Q95
A 40-year-old woman with well-controlled hypertension on ramipril presents requesting contraception. Her blood pressure today is 134/86 mmHg. She has been normotensive on treatment for the past year with no end-organ damage. Her BMI is 26 kg/m², and she is a non-smoker. She has regular periods and no other medical problems. She would prefer not to use an intrauterine device. According to UKMEC guidelines, which contraceptive method would be classified as category 2 (benefits generally outweigh risks) for this patient?
Q96
A 53-year-old woman commenced on continuous combined HRT 3 months ago presents with bilateral breast tenderness and swelling. She had significant vasomotor symptoms which have improved on treatment. Her mother had breast cancer diagnosed at age 68. Examination reveals symmetrically enlarged, tender breasts with no discrete masses. What is the most appropriate initial management?
Q97
A 44-year-old woman with menorrhagia has been using a levonorgestrel intrauterine system for 18 months with good symptom control. She now presents with a 6-week history of deep dyspareunia and intermittent lower abdominal pain. Bimanual examination reveals a bulky, tender uterus with reduced mobility and tenderness in the posterior fornix. The IUS threads are visible. A transvaginal ultrasound shows a retroverted uterus, bulky adenomyotic uterus, and the LNG-IUS in the correct fundal position. What is the most likely cause of her symptoms?
Q98
A 25-year-old woman presents 36 hours after unprotected sexual intercourse requesting emergency contraception. She is on day 12 of her menstrual cycle with regular 28-day cycles. She takes no regular medications and has no medical contraindications. She does not wish to have an intrauterine device inserted. What is the most effective oral emergency contraception for this patient?
Q99
A 57-year-old woman attends for review. She started estrogen-only HRT (transdermal 17β-estradiol 50 mcg) 2 years ago following total hysterectomy for fibroids. Her vasomotor symptoms are now well controlled. She asks about how long she should continue treatment and whether she needs any investigations. What is the most appropriate advice regarding duration and monitoring of her HRT?
Q100
A 36-year-old woman with a history of venous thromboembolism 2 years ago following a long-haul flight requests contraception. She completed 6 months of anticoagulation and thrombophilia screening revealed no underlying abnormality. She is a non-smoker with BMI of 28 kg/m². She does not wish to become pregnant for at least 5 years. What is the most appropriate contraceptive method according to UKMEC classification?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 91: A 45-year-old woman presents with a 12-month history of irregular menstrual cycles, hot flushes, and mood changes. She requests contraception as she remains sexually active. Her last menstrual period was 8 weeks ago. She has a BMI of 28 kg/m², blood pressure 135/85 mmHg, and no significant medical history. She smokes 5 cigarettes per day. What is the most appropriate management approach?
A. Advise that contraception is not needed as she is likely postmenopausal
B. Prescribe combined oral contraceptive pill for contraception and symptom control
C. Prescribe levonorgestrel intrauterine system with sequential HRT
D. Arrange FSH testing to confirm menopausal status before considering contraception
E. Prescribe progesterone-only pill and advise on smoking cessation (Correct Answer)
Explanation: ***Prescribe progesterone-only pill and advise on smoking cessation***
- Women over **45 years old** with perimenopausal symptoms still require **contraception** until they have been amenorrhoeic for **two years** (if under 50) or **one year** (if over 50).
- The **Progesterone-Only Pill (POP)** is a safe choice (UKMEC 1) for this patient, unlike combined methods which are restricted due to her **age and smoking status**.
*Advise that contraception is not needed as she is likely postmenopausal*
- Postmenopause is only diagnosed clinically after **12 months of amenorrhoea** in a woman over 50, or **24 months** if under 50.
- Ovulation can still occur during the **perimenopause**, meaning there is a persistent, albeit reduced, **risk of pregnancy**.
*Prescribe combined oral contraceptive pill for contraception and symptom control*
- The **Combined Oral Contraceptive Pill (COCP)** is generally avoided in women over **35 who smoke** (UKMEC 3) due to an increased risk of **venous thromboembolism** and stroke.
- While it effective for symptom control, her smoking history makes the safety profile less favorable compared to **progestogen-only** methods.
*Prescribe levonorgestrel intrauterine system with sequential HRT*
- While the **LNG-IUS** is an excellent option for both contraception and the **progestogenic component of HRT**, it involves an invasive procedure that may not be her first choice.
- **Sequential HRT** is used for symptom relief, but the initial priority is providing safe, simple **contraception** while managing lifestyle factors like smoking.
*Arrange FSH testing to confirm menopausal status before considering contraception*
- **FSH testing** is not routinely recommended to diagnose menopause or perimenopause in women over **45 years of age** based on clinical guidelines.
- A single FSH level is unreliable due to **hormonal fluctuations** during the perimenopause and would not change the current need for **effective contraception**.
Question 92: A 34-year-old woman with well-controlled rheumatoid arthritis on methotrexate 15 mg weekly requests contraception. She is in a new relationship and wishes to avoid pregnancy while continuing her current treatment. She has no other medical conditions, does not smoke, and has a BMI of 23 kg/m². What is the most important counselling point regarding contraception for this patient?
A. She should use barrier methods only as all hormonal contraceptives are contraindicated with methotrexate
B. She requires highly effective contraception due to the teratogenic risk of methotrexate (Correct Answer)
C. She should discontinue methotrexate before starting any contraceptive method
D. Combined hormonal contraception is contraindicated due to increased risk of disease flare
E. The levonorgestrel intrauterine system is contraindicated due to immunosuppression risk
Explanation: ***She requires highly effective contraception due to the teratogenic risk of methotrexate***
- **Methotrexate** is a known **teratogen** that can cause severe birth defects and miscarriages due to its anti-folate mechanism.
- Given this high risk, it is crucial for patients on methotrexate to use **highly effective contraception** to prevent pregnancy, continuing for at least **3 to 6 months** after discontinuing the drug.
*She should use barrier methods only as all hormonal contraceptives are contraindicated with methotrexate*
- **Hormonal contraceptives** are generally safe and **highly effective**, making them appropriate choices for women on methotrexate, unlike the false premise that they are contraindicated.
- Relying solely on **barrier methods** is considered insufficient due to their higher failure rates, which poses an unacceptable risk given the **teratogenicity** of methotrexate.
*She should discontinue methotrexate before starting any contraceptive method*
- Discontinuing **methotrexate** is medically inadvisable as it could lead to a **flare** of her well-controlled **rheumatoid arthritis**, undermining her disease management.
- Contraception should be initiated **prior to or concurrently** with methotrexate therapy to ensure continuous protection against pregnancy without interrupting essential treatment.
*Combined hormonal contraception is contraindicated due to increased risk of disease flare*
- There is **no evidence** to suggest that **combined hormonal contraception (CHC)** increases the risk of **rheumatoid arthritis flares**; some studies even suggest a potential stabilizing effect on disease activity.
- Given her favorable profile (non-smoker, BMI 23), she is a good candidate for CHC, as her **cardiovascular risks** are low.
*The levonorgestrel intrauterine system is contraindicated due to immunosuppression risk*
- The **levonorgestrel intrauterine system (LNG-IUS)** is a **Long-Acting Reversible Contraceptive (LARC)** and is considered a safe and highly effective option for women on **immunosuppressive therapy** like methotrexate.
- There is no increased risk of **infection** or **pelvic inflammatory disease (PID)** associated with LNG-IUS use in patients with well-controlled rheumatoid arthritis on methotrexate.
Question 93: A 52-year-old woman with a history of endometriosis presents with menopausal symptoms including severe hot flushes and night sweats for 6 months. She had a total hysterectomy without oophorectomy 8 years ago. Her FSH level is 67 IU/L. She is keen to start HRT but is concerned about symptom recurrence. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate initial HRT regimen?
A. Continuous combined estrogen and progestogen HRT
B. Sequential combined estrogen and progestogen HRT
C. Estrogen-only HRT with add-back progestogen
D. Estrogen-only HRT (Correct Answer)
E. Tibolone
Explanation: ***Estrogen-only HRT***
- In women who have undergone a **total hysterectomy**, the risk of **endometrial hyperplasia** is eliminated, making progesterone for endometrial protection unnecessary.
- While the patient has a history of **endometriosis**, estrogen-only therapy remains the first-line choice because the risk of reactivating residual tissue is generally low and outweighed by managing severe **vasomotor symptoms**.
*Continuous combined estrogen and progestogen HRT*
- This regimen is typically reserved for women with an **intact uterus** to prevent endometrial cancer through continuous progestogen exposure.
- Using progestogen in this patient unnecessarily increases the risk of side effects like **breast tenderness** and slightly higher **breast cancer** risk without clear benefit.
*Sequential combined estrogen and progestogen HRT*
- Typically used for **perimenopausal** women with a uterus to provide predictable withdrawal bleeds.
- Since this patient has had a **hysterectomy**, there is no endometrium to shed, making this complex regimen inappropriate.
*Estrogen-only HRT with add-back progestogen*
- Add-back therapy is sometimes considered if there is known **extensive residual endometriosis**, but it is not the standard initial step post-hysterectomy.
- It complicates the regimen and should only be initiated if symptoms of **endometriosis recurrence** (like pelvic pain) actually develop.
*Tibolone*
- Tibolone is a synthetic compound with **estrogenic, progestogenic, and androgenic** properties that can be used post-menopause.
- While it is an option for women with a history of endometriosis to avoid estrogenic stimulation, standard **estrogen-only HRT** is more conventional for initial management of severe flashes.
Question 94: A 27-year-old woman presents requesting contraception. She has a history of multiple sclerosis diagnosed 3 years ago with limited mobility. She is currently wheelchair-bound and experiences frequent urinary tract infections. Her BMI is 24 kg/m². She does not smoke and has no other significant medical history. She is in a stable relationship and has completed her family. What is the most appropriate contraceptive method for this patient?
A. Combined oral contraceptive pill
B. Progesterone-only pill
C. Copper intrauterine device
D. Levonorgestrel intrauterine system (Correct Answer)
E. Etonogestrel subdermal implant
Explanation: ***Levonorgestrel intrauterine system***
- The **LNG-IUS** is ideal for this patient because it avoids the high **VTE risk** associated with immobility/wheelchair use in **multiple sclerosis** (UKMEC 3-4 for combined methods).
- It provides highly effective **long-acting reversible contraception (LARC)** and offers the benefit of **reduced menstrual bleeding**, which simplifies hygiene for patients with **limited mobility**.
*Combined oral contraceptive pill*
- This is contraindicated (**UKMEC 4**) because the patient's **prolonged immobility** and wheelchair use significantly increase the risk of **venous thromboembolism (VTE)**.
- Estrogen-containing methods are avoided in **multiple sclerosis** patients who are not fully ambulatory due to this synergistic **thrombotic risk**.
*Progesterone-only pill*
- While it is safe regarding **VTE risk**, it is less effective than **LARC** methods and requires strict daily adherence, which may be more difficult with chronic illness.
- The **LNG-IUS** is preferred over the POP because it provides superior **menstrual suppression**, which is a significant quality-of-life benefit for this patient.
*Copper intrauterine device*
- Although it does not increase VTE risk, the **Copper IUD** is often associated with **heavier or more painful periods**, which is undesirable for someone with limited mobility.
- The lack of hormonal benefits for **menstrual control** makes it a less optimal choice compared to the **Levonorgestrel intrauterine system**.
*Etonogestrel subdermal implant*
- The **implant** is a safe **LARC** option with no estrogen-related VTE risk, but it frequently causes **unpredictable bleeding** patterns.
- In contrast, the **LNG-IUS** more consistently leads to **amenorrhea or oligomenorrhea**, which is clinically more beneficial for managing hygiene in a **wheelchair-bound** patient.
Question 95: A 40-year-old woman with well-controlled hypertension on ramipril presents requesting contraception. Her blood pressure today is 134/86 mmHg. She has been normotensive on treatment for the past year with no end-organ damage. Her BMI is 26 kg/m², and she is a non-smoker. She has regular periods and no other medical problems. She would prefer not to use an intrauterine device. According to UKMEC guidelines, which contraceptive method would be classified as category 2 (benefits generally outweigh risks) for this patient?
A. Combined oral contraceptive pill (Correct Answer)
B. Levonorgestrel intrauterine system
C. Etonogestrel contraceptive implant
D. Copper intrauterine device
E. Progestogen-only pill
Explanation: ***Combined oral contraceptive pill***
- For women with **adequately controlled hypertension** (consistently <140/90 mmHg), the **COCP** is classified as **UKMEC 2**, meaning benefits generally outweigh the risks.
- While estrogen can slightly increase blood pressure, it is acceptable in this patient because she is a **non-smoker**, has a BMI <30, and no **target organ damage**.
*Levonorgestrel intrauterine system*
- All **intrauterine devices** (including hormonal systems like LNG-IUS) are classified as **UKMEC 1** for patients with hypertension.
- Although a safe option, it is not the correct answer because the question specifically asks for a **UKMEC 2** classification and the patient prefers not to use an IUD.
*Etonogestrel contraceptive implant*
- The **contraceptive implant** is typically classified as **UKMEC 1** for patients with controlled or mildly elevated blood pressure.
- It does not contain **estrogen**, which is the primary component restricted in hypertensive patients, thus having fewer restrictions than the COCP.
*Copper intrauterine device*
- The **Copper IUD** is a non-hormonal method and is classified as **UKMEC 1** for all degrees of hypertension.
- This method has no effect on blood pressure or **cardiovascular risk**, but it was specifically declined by the patient.
*Progestogen-only pill*
- For patients with **adequately controlled hypertension**, the **POP** is classified as **UKMEC 1**.
- It is only upgraded to **UKMEC 2** if the systolic blood pressure is 140–159 mmHg or the diastolic is 90–99 mmHg.
Question 96: A 53-year-old woman commenced on continuous combined HRT 3 months ago presents with bilateral breast tenderness and swelling. She had significant vasomotor symptoms which have improved on treatment. Her mother had breast cancer diagnosed at age 68. Examination reveals symmetrically enlarged, tender breasts with no discrete masses. What is the most appropriate initial management?
A. Stop HRT immediately and refer urgently to breast clinic under 2-week-wait pathway
B. Continue current HRT and arrange routine mammography
C. Reduce the estrogen dose of her current HRT preparation (Correct Answer)
D. Switch to tibolone which has less breast adverse effects
E. Add continuous progestogen to reduce breast symptoms
Explanation: ***Reduce the estrogen dose of her current HRT preparation***
- **Breast tenderness and swelling** are common side effects during the initial months of HRT due to **estrogen stimulation** of breast tissue.
- Reducing the **estrogen dose** typically alleviates these symptoms while maintaining control of **vasomotor symptoms**, making it the most appropriate initial management step.
*Stop HRT immediately and refer urgently to breast clinic under 2-week-wait pathway*
- **Urgent referral** is not indicated as clinical findings are **bilateral and symmetrical** without discrete masses, which are typically benign features of HRT side effects.
- Immediate cessation is unnecessary given the symptoms are expected **side effects** of recent treatment initiation rather than signs of malignancy; the family history of breast cancer at 68 is not an immediate red flag for this presentation.
*Continue current HRT and arrange routine mammography*
- While symptoms may settle over time, the patient is currently symptomatic; management should focus on **dose adjustment** rather than just observation.
- Mammography should follow the **national screening program** guidelines, and there is no indication for diagnostic imaging of bilateral, symmetrical physiological tenderness outside of these guidelines.
*Switch to tibolone which has less breast adverse effects*
- **Tibolone** is an alternative, but it is premature to switch medication classes before attempting a simple **dose reduction** of the current effective regimen.
- Dose titration is the standard first-line approach for managing **hormone-related side effects** within the first 3-6 months of HRT.
*Add continuous progestogen to reduce breast symptoms*
- The patient is already on **continuous combined HRT**, meaning she is already receiving daily progestogen to protect the endometrium.
- Adding extra progestogen does not mitigate **estrogen-induced** breast swelling and may introduce additional side effects like mood changes or bloating.
Question 97: A 44-year-old woman with menorrhagia has been using a levonorgestrel intrauterine system for 18 months with good symptom control. She now presents with a 6-week history of deep dyspareunia and intermittent lower abdominal pain. Bimanual examination reveals a bulky, tender uterus with reduced mobility and tenderness in the posterior fornix. The IUS threads are visible. A transvaginal ultrasound shows a retroverted uterus, bulky adenomyotic uterus, and the LNG-IUS in the correct fundal position. What is the most likely cause of her symptoms?
A. IUS malposition causing pain
B. Pelvic inflammatory disease secondary to IUS
C. Progression of underlying adenomyosis (Correct Answer)
D. Development of endometrial cancer
E. IUS perforation into the pouch of Douglas
Explanation: ***Progression of underlying adenomyosis***
- The ultrasound and physical examination confirm a **bulky, tender uterus** and adenomyotic changes, which typically progress over time despite hormonal control of bleeding.
- While the **LNG-IUS** effectively manages **menorrhagia**, it does not halt the structural progression of adenomyosis, leading to new-onset **deep dyspareunia** and pelvic pain.
*IUS malposition causing pain*
- The **transvaginal ultrasound** explicitly states that the LNG-IUS is in the **correct fundal position**.
- Visible **IUS threads** during the clinical examination further support that the device has not displaced significantly from the uterine cavity.
*Pelvic inflammatory disease secondary to IUS*
- The risk of **PID** related to IUS insertion is highest within the first **20 days**; this patient has had the device for 18 months.
- The absence of **fever**, abnormal discharge, and the specific ultrasound findings make a chronic infectious process less likely than a structural progression.
*Development of endometrial cancer*
- The **LNG-IUS** provides high levels of local progestogen, which offers significant **endometrial protection** against hyperplasia and malignancy.
- Endometrial cancer usually presents with **postmenopausal** or abnormal bleeding rather than the **bulky, tender uterus** and dyspareunia seen here.
*IUS perforation into the pouch of Douglas*
- A **perforation** typically occurs during insertion, and the ultrasound clearly visualizes the device within the **fundal position** of the uterus.
- If perforation had occurred, the **IUS threads** would likely be retracted and not visible on bimanual examination.
Question 98: A 25-year-old woman presents 36 hours after unprotected sexual intercourse requesting emergency contraception. She is on day 12 of her menstrual cycle with regular 28-day cycles. She takes no regular medications and has no medical contraindications. She does not wish to have an intrauterine device inserted. What is the most effective oral emergency contraception for this patient?
A. Levonorgestrel 1.5 mg as she is within 72 hours
B. Ulipristal acetate 30 mg as it is more effective around ovulation (Correct Answer)
C. Double dose levonorgestrel 3 mg due to timing in cycle
D. Either levonorgestrel or ulipristal acetate as they are equally effective
E. No emergency contraception needed as she is in the proliferative phase
Explanation: ***Ulipristal acetate 30 mg as it is more effective around ovulation***
- **Ulipristal acetate (UPA)** is the first-line oral choice for this patient because it is more effective than levonorgestrel in the **periovulatory period** (days 10–14 of a 28-day cycle), and she is on day 12.
- UPA can delay or inhibit **ovulation** even after the **LH surge** has begun, providing a wider window of effectiveness closer to actual ovulation compared to levonorgestrel.
*Levonorgestrel 1.5 mg as she is within 72 hours*
- While **levonorgestrel (LNG)** is effective within 72 hours, its efficacy significantly decreases when taken close to **ovulation**, especially after the **LH surge** has started.
- LNG primarily works by preventing or delaying ovulation *before* the LH surge, making it less effective than UPA in the patient's fertile window.
*Double dose levonorgestrel 3 mg due to timing in cycle*
- A **double dose** of levonorgestrel (3 mg) is not standard practice for increasing efficacy based on **menstrual cycle timing** alone.
- This higher dose is typically considered only for patients with a **BMI >30 kg/m² or weight >75 kg**, or those on **enzyme-inducing medications**, none of which are mentioned here.
*Either levonorgestrel or ulipristal acetate as they are equally effective*
- This statement is incorrect; **ulipristal acetate** has been shown to be more effective than **levonorgestrel**, particularly when taken closer to ovulation and up to 120 hours post-coitus.
- In the **periovulatory period**, UPA maintains higher efficacy in preventing pregnancy compared to LNG.
*No emergency contraception needed as she is in the proliferative phase*
- Day 12 of a regular 28-day cycle falls within the **fertile window** and is very close to the expected day of **ovulation** (typically day 14).
- Given that **sperm** can survive for up to 5 days, unprotected intercourse on day 12 carries a high risk of conception, necessitating emergency contraception.
Question 99: A 57-year-old woman attends for review. She started estrogen-only HRT (transdermal 17β-estradiol 50 mcg) 2 years ago following total hysterectomy for fibroids. Her vasomotor symptoms are now well controlled. She asks about how long she should continue treatment and whether she needs any investigations. What is the most appropriate advice regarding duration and monitoring of her HRT?
A. Continue HRT indefinitely as benefits outweigh risks with estrogen-only therapy after hysterectomy
B. Stop HRT now as 2 years is the maximum recommended duration
C. Continue for up to 5 years total, then mandatory discontinuation
D. Continue while symptoms persist with annual review; no routine investigations needed (Correct Answer)
E. Continue only if mammography and bone density scans are normal
Explanation: ***Continue while symptoms persist with annual review; no routine investigations needed***- There is no **arbitrary time limit** for HRT use; it should be continued as long as the benefits outweigh the risks and symptoms persist.- Decision making involves an **annual review** of symptoms and risks, with no mandatory investigations required specifically for HRT monitoring.*Continue HRT indefinitely as benefits outweigh risks with estrogen-only therapy after hysterectomy*- While **estrogen-only HRT** has a more favorable risk profile than combined therapy, it should still be subject to **annual individual assessment** rather than an "indefinite" prescription.- This approach ignores the necessity of periodic trials of **dose reduction** or discontinuation to see if vasomotor symptoms have naturally resolved.*Stop HRT now as 2 years is the maximum recommended duration*- A two-year limit is medically unsupported; symptoms can last for many years, and **NICE guidelines** do not set a fixed maximum duration.- Stopping treatment prematurely can lead to a return of **vasomotor symptoms** and a loss of bone protective benefits.*Continue for up to 5 years total, then mandatory discontinuation*- The "5-year rule" is often cited regarding **combined HRT** and breast cancer risk, but it is not a mandatory cutoff for estrogen-only therapy.- Treatment duration should be **individualized** based on the patient's quality of life and clinical profile rather than a fixed number of years.*Continue only if mammography and bone density scans are normal*- Routine **bone density scans** are not indicated for monitoring HRT unless there are specific clinical risk factors for osteoporosis.- While **mammography** should continue as per the national screening program, it is not a prerequisite for the continuation of estrogen-only HRT.
Question 100: A 36-year-old woman with a history of venous thromboembolism 2 years ago following a long-haul flight requests contraception. She completed 6 months of anticoagulation and thrombophilia screening revealed no underlying abnormality. She is a non-smoker with BMI of 28 kg/m². She does not wish to become pregnant for at least 5 years. What is the most appropriate contraceptive method according to UKMEC classification?
A. Combined oral contraceptive pill as the VTE was provoked and she has no thrombophilia
B. Desogestrel progestogen-only pill
C. Etonogestrel contraceptive implant
D. Copper intrauterine device (Correct Answer)
E. Depot medroxyprogesterone acetate injection
Explanation: ***Copper intrauterine device***
- The copper IUD is classified as **UKMEC 1** (no restriction) for patients with a history of **venous thromboembolism (VTE)** because it is a non-hormonal method with no effect on coagulation.
- It is highly appropriate for this patient as it provides effective **long-acting reversible contraception (LARC)** for 5 to 10 years, meeting her requirement for long-term pregnancy prevention.
*Combined oral contraceptive pill as the VTE was provoked and she has no thrombophilia*
- Any history of VTE, regardless of being provoked or having a negative thrombophilia screen, is classified as **UKMEC 4** (unacceptable health risk) for combined hormonal contraception.
- The **estrogen component** significantly increases the risk of recurrent thrombosis, making it strictly contraindicated in this clinical scenario.
*Desogestrel progestogen-only pill*
- A history of VTE is categorized as **UKMEC 2** (benefits generally outweigh risks) for the progestogen-only pill (POP), although some guidelines previously considered it UKMEC 3 for active VTE.
- While safer than combined methods, it requires daily compliance and is less ideal than the **UKMEC 1** copper IUD for a patient seeking long-term 5-year protection.
*Etonogestrel contraceptive implant*
- The contraceptive implant is categorized as **UKMEC 2** for patients with a history of VTE, indicating that the benefits generally outweigh the theoretical risks.
- Although a valid LARC option, it only lasts for **3 years**, which does not fully meet the patient's request for at least **5 years** of contraception.
*Depot medroxyprogesterone acetate injection*
- Injectable progestogens like DMPA are classified as **UKMEC 2** for women with a previous history of VTE.
- While it provides effective contraception, the **Copper IUD** is superior in this case due to its **UKMEC 1** status and its ability to provide protection for the full 5-year duration requested.
